PL1670514T3 - Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II - Google Patents

Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II

Info

Publication number
PL1670514T3
PL1670514T3 PL04773539T PL04773539T PL1670514T3 PL 1670514 T3 PL1670514 T3 PL 1670514T3 PL 04773539 T PL04773539 T PL 04773539T PL 04773539 T PL04773539 T PL 04773539T PL 1670514 T3 PL1670514 T3 PL 1670514T3
Authority
PL
Poland
Prior art keywords
inhibitor
topoisomerase
histone deacetylase
antitumor agent
deacetylase inhibitor
Prior art date
Application number
PL04773539T
Other languages
English (en)
Polish (pl)
Inventor
Yoshinori Naoe
Yuka Sasakawa
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of PL1670514T3 publication Critical patent/PL1670514T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PL04773539T 2003-09-25 2004-09-24 Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II PL1670514T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2003334340 2003-09-25
JP2003344315 2003-10-02
PCT/JP2004/014451 WO2005030239A2 (en) 2003-09-25 2004-09-24 Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor
EP04773539A EP1670514B1 (en) 2003-09-25 2004-09-24 Antitumor agent comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor

Publications (1)

Publication Number Publication Date
PL1670514T3 true PL1670514T3 (pl) 2010-11-30

Family

ID=34380371

Family Applications (2)

Application Number Title Priority Date Filing Date
PL10163527T PL2263694T3 (pl) 2003-09-25 2004-09-24 Środek przeciwnowotworowy zawierający FK228 jako inhibitor deacetylazy histonowej i doksorubicynę jako inhibitor topoizomerazy II
PL04773539T PL1670514T3 (pl) 2003-09-25 2004-09-24 Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL10163527T PL2263694T3 (pl) 2003-09-25 2004-09-24 Środek przeciwnowotworowy zawierający FK228 jako inhibitor deacetylazy histonowej i doksorubicynę jako inhibitor topoizomerazy II

Country Status (14)

Country Link
US (1) US7314862B2 (US07314862-20080101-C00003.png)
EP (2) EP2263694B1 (US07314862-20080101-C00003.png)
JP (1) JP4779971B2 (US07314862-20080101-C00003.png)
AT (1) ATE471740T1 (US07314862-20080101-C00003.png)
CA (1) CA2540108A1 (US07314862-20080101-C00003.png)
CY (1) CY1114359T1 (US07314862-20080101-C00003.png)
DE (1) DE602004027824D1 (US07314862-20080101-C00003.png)
DK (1) DK2263694T3 (US07314862-20080101-C00003.png)
ES (2) ES2425083T3 (US07314862-20080101-C00003.png)
MX (1) MXPA06003222A (US07314862-20080101-C00003.png)
PL (2) PL2263694T3 (US07314862-20080101-C00003.png)
PT (1) PT2263694E (US07314862-20080101-C00003.png)
SI (1) SI2263694T1 (US07314862-20080101-C00003.png)
WO (1) WO2005030239A2 (US07314862-20080101-C00003.png)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE526029T1 (de) * 2001-08-21 2011-10-15 Astellas Pharma Inc Medizinische verwendung eines histon-deacetylase- hemmers und verfahren zur beurteilung seiner antitumoralen wirkung
AU2003219555A1 (en) * 2002-04-05 2003-10-20 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
KR20050106438A (ko) * 2003-02-19 2005-11-09 아스텔라스세이야쿠 가부시키가이샤 히스톤 디아세틸라제 저해제의 항종양 효과의 예측방법
KR20050122210A (ko) * 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
EP2263694B1 (en) 2003-09-25 2013-06-12 Astellas Pharma Inc. Antitumor agent comprising the histone deacetylase inhibitor FK228 and the topoisomerase II inhibitor doxorubicin
WO2005066151A2 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20050159470A1 (en) * 2003-12-19 2005-07-21 Syrrx, Inc. Histone deacetylase inhibitors
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
JP2008524246A (ja) * 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
JP2008540574A (ja) * 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
CN101263121A (zh) * 2005-07-14 2008-09-10 塔克达圣地亚哥公司 组蛋白脱乙酰基酶抑制剂
WO2007040522A1 (en) * 2005-09-30 2007-04-12 The Ohio State Research Foundation Antitumor agents
EP1965824A4 (en) * 2005-11-18 2011-10-19 Gloucester Pharmaceuticals Inc METABOLITENE DERIVATIVES OF HDAC INHIBITOR FK228
JP2009525955A (ja) * 2006-01-13 2009-07-16 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
EP2049139A4 (en) * 2006-04-24 2009-06-24 Gloucester Pharmaceuticals Inc TREATMENT OF TUMORS EXPRESSING RAS
US8957027B2 (en) 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
PL2099442T3 (pl) 2006-12-26 2015-04-30 Pharmacyclics Inc Sposób stosowania inhibitorów deacetylazy histonów i monitoringu biomarkerów w terapii skojarzonej
AU2007342030B2 (en) * 2006-12-29 2013-08-15 Celgene Corporation Romidepsin-based treatments for cancer
MX2009006969A (es) * 2006-12-29 2010-04-07 Gloucester Pharmaceuticals Purificacion de romidepsina.
WO2009002941A1 (en) * 2007-06-22 2008-12-31 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by histone deacetylase inhibitors
US20110021517A1 (en) * 2008-02-26 2011-01-27 Nerviano Medical Sciences S.R.L. Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
SG10201505475XA (en) 2010-07-12 2015-09-29 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
AU2011376953B2 (en) 2011-09-13 2017-08-24 Pharmacyclics Llc Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
JP6253591B2 (ja) * 2012-11-01 2017-12-27 公益財団法人微生物化学研究会 抗がん剤、及び併用抗がん剤
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
CN116327887B (zh) * 2023-04-24 2023-11-03 南京捷因诊断技术有限公司 一种lsd1抑制剂作为抗肿瘤药物的应用

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US574455A (en) * 1897-01-05 Switch-lock
US486379A (en) * 1892-11-15 Hame-tug
US3997633A (en) * 1975-06-24 1976-12-14 Max Leva Contact towers with leak-proof support of improved plate subassembly
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4348388A (en) * 1980-04-02 1982-09-07 G.D. Searle & Co. 11-Amino-11-deoxydaunorubicin and analogs
GB8426672D0 (en) * 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
US4950755A (en) * 1985-08-12 1990-08-21 Ohio State University Bis(morpholinomethyl) derivative of 1,2-bis(dioxopiperizinyl)propane
US5242901A (en) * 1988-01-27 1993-09-07 New York University Reduction of anthracycline induced cardiotoxicity
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
US5514664A (en) * 1990-05-26 1996-05-07 Byk Gulden Lomberg Chemische Fabrik Gmbh 1,4-dihydropyridines for application in combatting resistance to drugs
US5620961A (en) * 1994-04-25 1997-04-15 Markovic; Nenad S. Fructose ester-β-cyclodextrin complexes and processes for making and using same
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US6020373A (en) * 1995-10-20 2000-02-01 Eastern Virginia Medical School Chelate derivatives as protectors against tissue injury
US5780054A (en) * 1996-01-17 1998-07-14 University Of British Columbia Methods for increasing the circulation half-life of protein-based therapeutics
WO1998029110A2 (en) * 1996-12-30 1998-07-09 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6451784B1 (en) * 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
US7229841B2 (en) * 2001-04-30 2007-06-12 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
US6286513B1 (en) * 1998-10-22 2001-09-11 Jessie L. Au Methods for treating superficial bladder carcinoma
US6197809B1 (en) * 1998-12-23 2001-03-06 Ardenia Investments Ltd. Compounds for the treatment of cancer
US20030144570A1 (en) * 1999-11-12 2003-07-31 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
KR101026205B1 (ko) * 1999-11-23 2011-03-31 메틸진 인코포레이티드 히스톤 디아세틸라제의 억제제
US6593308B2 (en) * 1999-12-03 2003-07-15 The Regents Of The University Of California Targeted drug delivery with a hyaluronan ligand
WO2001042282A1 (en) 1999-12-08 2001-06-14 Xcyte Therapies, Inc. Depsipeptide and congeners thereof for use as immunosuppressants
US20020028237A1 (en) * 2000-04-20 2002-03-07 Colbern Gail T. Method for reducing toxicity of a cytotoxic agent
ES2321584T3 (es) * 2000-07-17 2009-06-09 Astellas Pharma Inc. Fk228 reducido y su uso.
WO2002024178A2 (en) * 2000-09-22 2002-03-28 Bristol-Myers Squibb Company Method for reducing toxicity of combined chemotherapies
CZ2003837A3 (cs) * 2000-09-22 2004-12-15 Bristol-Myers Squibb Company Způsob pro snížení toxicity při kombinovaných chemoterapiích
AU2002235175A1 (en) * 2000-12-06 2002-06-18 Tularik, Inc. Lometrexol combination therapy
AU2002240066A1 (en) * 2001-01-26 2002-08-06 University Of Chicago Determination of ugt2b7 gene polymorphisms for predicting ugt2b7 substrate toxicity and for optimising drug dosage
ATE450265T1 (de) * 2001-03-23 2009-12-15 Shire Canada Inc Pharmazeutische mischung zur behandlung von krebs,die dioxolan nukleosidanalogen enthält
US6905669B2 (en) * 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
ATE526029T1 (de) * 2001-08-21 2011-10-15 Astellas Pharma Inc Medizinische verwendung eines histon-deacetylase- hemmers und verfahren zur beurteilung seiner antitumoralen wirkung
AU2003219555A1 (en) * 2002-04-05 2003-10-20 Fujisawa Pharmaceutical Co., Ltd. Depsipeptide for therapy of kidney cancer
UA81628C2 (uk) * 2002-05-17 2008-01-25 Авентіс Фарма С.А. Застосування доцетакселу/доксорубіцину/циклофосфаміду у допоміжній терапії раку молочної залози
US20040136905A1 (en) * 2002-10-15 2004-07-15 Kent Thomas B. Magnetically guided particles for radiative therapies
US20040152632A1 (en) * 2002-11-06 2004-08-05 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
WO2004064727A2 (en) 2003-01-16 2004-08-05 Georgetown University Method of cancer treatment using hdac inhibitors
CA2526908A1 (en) * 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
PE20050206A1 (es) 2003-05-26 2005-03-26 Schering Ag Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
ES2341771T3 (es) * 2003-06-27 2010-06-28 Astellas Pharma Inc. Agente terapeutico contra el sarcoma de tejidos blandos.
EP2263694B1 (en) 2003-09-25 2013-06-12 Astellas Pharma Inc. Antitumor agent comprising the histone deacetylase inhibitor FK228 and the topoisomerase II inhibitor doxorubicin
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent

Also Published As

Publication number Publication date
MXPA06003222A (es) 2006-05-22
US20050070467A1 (en) 2005-03-31
DK2263694T3 (da) 2013-08-26
ES2344899T3 (es) 2010-09-09
WO2005030239A3 (en) 2005-07-28
SI2263694T1 (sl) 2013-09-30
CY1114359T1 (el) 2016-08-31
JP4779971B2 (ja) 2011-09-28
PT2263694E (pt) 2013-08-27
US7314862B2 (en) 2008-01-01
DE602004027824D1 (de) 2010-08-05
JP2007506647A (ja) 2007-03-22
PL2263694T3 (pl) 2013-11-29
EP2263694A1 (en) 2010-12-22
EP1670514A2 (en) 2006-06-21
CA2540108A1 (en) 2005-04-07
EP1670514B1 (en) 2010-06-23
EP2263694B1 (en) 2013-06-12
ES2425083T3 (es) 2013-10-11
ATE471740T1 (de) 2010-07-15
WO2005030239A2 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
PL1670514T3 (pl) Środek przeciwnowotworowy zawierający inhibitor deacetylazy histonowej i inhibitor topoizomerazy II
TW200738725A (en) Unsaturated mTOR inhibitors
MY146111A (en) Acylaminopyrazoles as fgfr inhibitors
RS17004A (sr) Alkin-arilski inhibitori fosfodiesteraze-4
TW200626131A (en) C-aryl glucoside SGLT2 inhibitors and method
MY148688A (en) 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
UA84712C2 (en) N-substituted pyrazolyl-amidyl-benzimidazolyl c-kit inhibitors
PL1940786T3 (pl) Pochodne bifenylowe i ich zastosowanie w leczeniu zapalenia wątroby typu C
WO2009156735A3 (en) New therapeutic agents
EP1778294A4 (en) ANTIMICROBIAL PHOTODYNAMIC THERAPY COMPOUND BASED ON ERYTHROSINE AND USE THEREOF
MY150697A (en) Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
MA27566A1 (fr) Inhibiteurs de 4-oxo-1-(3-phenyle substitue -1, 4-dihydro-1, 8-naphthyridine-3-carboxamide phosphodiesterase-4
TW200519111A (en) N3-substituted imidazopyridine C-KIT inhibitors
IL178261A0 (en) Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
IL174121A0 (en) Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
HK1080447B (zh) 視黃醇衍生物、它們在治療癌症和增强其它細胞毒性劑功效中的應用
AU2002364211A1 (en) Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
WO2006055621A3 (en) Histone deacetylase inhibitors and methods of use
MXPA03010761A (es) Combinaciones farmaceuticas.
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
UA96969C2 (en) Acylaminopyrazoles as fgfr inhibitors
TW200508199A (en) Novel compound
MX2007002600A (es) Mercaptoamidas como inhibidores de la histona deacetilasa.
AU2003258630A1 (en) Pyrimidine derivatives as selective cox-2 inhibitors